Biotech

All Articles

Ascendis' dwarfism medication favorites in period 3, intimidates BioMarin

.Ascendis Pharma has actually emerged as a possible threat to BioMarin's Voxzogo, reporting phase 3 ...

Despite ph. 3 miss, Alkeus views course ahead of time for eye illness asset

.Though Alkeus Pharmaceuticals' oral eye disease property stopped working to dramatically lessen geo...

Kairos goes social with $6M IPO to cash tests of cancer cells medication

.With a triad of biotechs attacking the Nasdaq on Friday, it was actually easy to overlook a smaller...

Vaccine and also Keytruda combination reliable in squamous cell carcinoma

.Immune system gate preventions are the superheroes of cancer cells treatment. Medications like Bris...

Cue Biopharma mark time J&ampJ vet as CBO-- Chutes &amp Ladders

.Accept to today's Chutes &amp Ladders, our roundup of significant management hirings, shootings and...

Regeneron's Opdualag competitor reveals 57% action fee

.Regeneron is back along with long-term consequence for its LAG-3 prevention and also PD-1 preventio...

AstraZeneca articles data on internal rivals to AbbVie, Pfizer ADCs

.AstraZeneca has actually shared an early consider the efficiency of its own internal antibody-drug ...

iTeos- GSK's TIGIT celebrity shows meaningful improvement

.After introducing a phase 3 launch based on favorable midstage end results, iTeos and also GSK are ...

More collective FDA can easily accelerate rare illness R&ampD: record

.The FDA should be actually a lot more open as well as collective to let loose a surge in approvals ...

Zenas, MBX, Bicara scalp to Nasdaq in hot time for biotech IPOs

.It is actually an extraordinarily busy Friday for biotech IPOs, with Zenas BioPharma, MBX and also ...